Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PharmaNordic ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5% 2.5%   Bankruptcy risk   29.4% 8.9% 5.2% 2.9% 2.4% 2.2% 11.3% 11.0%   Credit score (0-100)   2 27 41 58 62 66 21 22   Credit rating   C BB BBB BBB BBB BBB BB BB   Credit limit (kDKK)   -0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   289 517 738 575 723 594 0.0 0.0   EBITDA   -52.7 257 363 172 294 140 0.0 0.0   EBIT   -52.7 257 363 172 294 140 0.0 0.0   Pre-tax profit (PTP)   -96.5 642.9 223.9 223.2 577.0 680.2 0.0 0.0   Net earnings   -87.8 574.4 144.4 183.3 515.4 647.8 0.0 0.0   Pre-tax profit without non-rec. items   -81.5 658 224 223 577 680 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   15.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -229 346 490 673 1,189 1,836 650 650   Interest-bearing liabilities   0.0 0.0 0.0 128 162 0.0 0.0 0.0   Balance sheet total (assets)   176 768 952 949 1,543 2,262 650 650   Net Debt   -88.9 -218 -660 -379 -217 -882 -650 -650     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   289 517 738 575 723 594 0.0 0.0   Gross profit growth   -39.3% 78.8% 42.9% -22.2% 25.8% -17.8% -100.0% 0.0%   Employees   0 0 0 0 0 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   176 768 952 949 1,543 2,262 650 650   Balance sheet change%   -37.7% 336.3% 24.0% -0.3% 62.6% 46.6% -71.2% 0.0%   Added value   -52.7 257.2 363.0 171.5 293.9 139.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -15 -15 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 1.0 2.0 3.0 4.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -18.2% 49.8% 49.2% 29.8% 40.7% 23.6% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -12.7% 112.3% 26.8% 23.3% 46.4% 35.8% 0.0% 0.0%   ROI %   -2,108.1% 381.3% 55.3% 34.4% 53.8% 42.7% 0.0% 0.0%   ROE %   -38.3% 220.3% 34.6% 31.5% 55.4% 42.8% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   -56.5% 45.0% 51.4% 70.9% 77.0% 81.2% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   168.7% -84.6% -181.9% -220.8% -73.8% -630.1% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 19.0% 13.6% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   1,151.5% 0.0% 0.0% -2.0% 1.0% 0.2% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   0.3 0.8 1.4 2.2 2.6 2.6 0.0 0.0   Current Ratio   0.3 0.8 1.4 2.2 2.6 2.6 0.0 0.0   Cash and cash equivalent   88.9 217.6 660.5 506.8 378.6 881.6 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -266.5 -78.7 197.9 330.8 561.6 676.6 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 140 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 140 0 0   EBIT / employee   0 0 0 0 0 140 0 0   Net earnings / employee   0 0 0 0 0 648 0 0